Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04072042
PHASE2

BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma

Sponsor: Ruijin Hospital

View on ClinicalTrials.gov

Summary

The aim of this study is to evaluate the efficacy and safety of Apatinib monotherapy for relapsed or refractory advanced bone and soft tissue sarcoma with VEGFR-2 (KDR) 604A\>G polymorphism as predictive biomarker

Official title: A Biomarker Driven, Open Label, Phase II Study of VEGFR2 Inhibitor Apatinib in Patients With Recurrent or Refractory Advanced Bone and Soft Tissue Sarcoma

Key Details

Gender

All

Age Range

8 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2019-10-30

Completion Date

2027-09-01

Last Updated

2025-05-14

Healthy Volunteers

No

Conditions

Interventions

DRUG

Apatinib monotherapy

patients will receive Apatinib 250mg tablet by mouth, bid.

Locations (1)

Ruijin Hospital Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China